Dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) combination therapy is used currently for melanoma and non–small lung carcinoma treatment and is more efficient than dabrafenib alone in inhibiting the pathway (18, 33). This evidence concerns the gene BRAF and melanoma.